<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03778112</url>
  </required_header>
  <id_info>
    <org_study_id>15060207</org_study_id>
    <nct_id>NCT03778112</nct_id>
  </id_info>
  <brief_title>MRI Guided SBRT for Localized Prostate Cancer</brief_title>
  <official_title>Prospective Evaluation of Multi-Parametric MRI Guided Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify
      patients for two different radiotherapy regimens based on the presence/absence of
      identifiable intraprostatic lesions.

      In patients without identifiable prostate cancer lesions, SBRT to the prostate in 5 sessions
      (fractions) will be administered.

      In patients with MRI-identified lesion(s), pelvic IMRT in 25 fractions will be administered
      followed by an SBRT prostate boost while simultaneously treating the prostate cancer
      lesion(s) to a higher dose in 3 fractions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy (RT) is considered standard of care treatment for prostate cancer. Conventional
      RT regimens consist of 8-9 weeks of daily RT. Recent data support the use of hypofractionated
      RT (5-6 weeks) due to similar disease control in a contracted treatment time. This study
      combines the benefits of RT dose escalation while shortening the overall RT treatment course.

      In this protocol, patients will undergo a pretreatment mpMRI prostate scan and be stratified
      to two separate SBRT regimens depending on whether prostate lesions are present. For patients
      without any positive mpMRI lesions, an SBRT monotherapy (36.25 Gy in 5 fractions) approach
      will be utilized. Patients with an equivocal or positive mpMRI lesion(s), will receive
      IG-IMRT (45 Gy in 25 fractions) to prostate and seminal vesicle +/- lymph nodes followed by a
      SBRT whole prostate boost (18 Gy in 3 fractions) with a simultaneously integrated boost (SIB)
      (21 Gy in 3 fractions) to intraprostatic lesion(s) only.

      Patients will be regularly assessed every 3 months for the first 2 years and then every 6
      months, indefinitely. Side effects will be monitored using the standardized international
      prostate symptom score (I-PSS) and Sexual Health Inventory of Men (SHIM) questionnaires at
      baseline and subsequent follow-up appointments.

      Hypothesis: MRI-guided treatment planning and delivery can selectively target high-risk
      prostate cancer nodules and deliver a higher effective RT dose, to achieve maximal tumor
      control without increasing toxicity, all in a shortened treatment duration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Late Radiation Induced Genitourinary and Gastrointestinal Toxicity</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Acute Radiation Induced Genitourinary Toxicity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Recurrence</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free-Survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Negative mpMRI Prostate Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT to the whole prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive mpMRI Prostate Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT to whole prostate</intervention_name>
    <description>Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate</description>
    <arm_group_label>Negative mpMRI Prostate Scan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions</intervention_name>
    <description>Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions</description>
    <arm_group_label>Positive mpMRI Prostate Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven prostate adenocarcinoma within 1 year of randomization

          -  NCCN Low to High Risk localized prostate cancer

          -  Zubrod Performance Status 0-1 within 60 days prior to registration

        Exclusion Criteria:

          -  Prior or concurrent invasive malignancy (except non-melanoma skin cancer)

          -  Regional Lymph Node (N1) involvement

          -  Distant Metastases (M1) involvement

          -  History of prior pelvic irradiation (external beam radiotherapy or brachytherapy)

          -  Prior chemotherapy

          -  Severe, active co-morbidities (unstable angina and/or CHF; MI; COPD; liver disease;
             AIDS)

          -  Acute bacterial or fungal infection requiring IV antibiotics

          -  Inability to undergo MRI

          -  Inability to receive fiducial markers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dian Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Stines, RN</last_name>
    <phone>312-563-0789</phone>
    <email>robert_stines@rush.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riley J Sticca, BS, CCRP</last_name>
    <phone>312-563-5769</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dian Wang, MD, PhD</last_name>
      <phone>312-942-5751</phone>
      <email>dian_wang@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mudit Chowdhary, MD</last_name>
      <phone>312-942-1210</phone>
      <email>mchowdharymd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dian Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mudit Chowdhary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

